US 10464994
Recombinant clusterin and use thereof in the treatment and prevention of disease
granted A61KA61K38/00A61K9/0019
Quick answer
US patent 10464994 (Recombinant clusterin and use thereof in the treatment and prevention of disease) held by The Board of Regents of the University of Texas System expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61K9/0019, A61K9/19, A61P